Literature DB >> 12027010

The 2.7 A structure of AChBP, homologue of the ligand-binding domain of the nicotinic acetylcholine receptor.

Katjusa Brejc1, Willem J van Dijk, August B Smit, Titia K Sixma.   

Abstract

Acetylcholine binding protein (AChBP) is a novel protein with high similarity to the extracellular domain of the nicotinic acetylcholine receptor. It is secreted from glia cells in the freshwater snail, Lymnaea stagnalis, where it modulates neuronal transmission. AChBP forms homopentamers with pharmacology that resembles the alpha7 nicotinic receptors. In the crystal structure of AChBP at 2.7 A, each protomer has a modified immunoglobulin fold. Almost all residues shown to be involved in ligand binding in the nicotinic receptor are found in a pocket at the subunit interface. This pocket is lined with aromatic residues, and filled with a HEPES buffer molecule. The AChBP crystal structure explains many of the biochemical studies on the nicotinic acetylcholine receptors. Surprisingly the interface between protomers is relatively weakly conserved between family members in the superfamily of pentameric ligand-gated ion channels. The lack of conservation has implications for the mechanism of gating of the ion channels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12027010

Source DB:  PubMed          Journal:  Novartis Found Symp        ISSN: 1528-2511


  16 in total

Review 1.  Agonist-activated ion channels.

Authors:  David Colquhoun
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 2.  Nicotinic receptors containing the alpha7 subunit: a model for rational drug design.

Authors:  G Sharma; S Vijayaraghavan
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 3.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.

Authors:  Antoine Taly; Pierre-Jean Corringer; Denis Guedin; Pierre Lestage; Jean-Pierre Changeux
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

Review 4.  Progress and challenges in the study of α6-containing nicotinic acetylcholine receptors.

Authors:  Sharon R Letchworth; Paul Whiteaker
Journal:  Biochem Pharmacol       Date:  2011-06-28       Impact factor: 5.858

5.  Functional Chimeras of GLIC Obtained by Adding the Intracellular Domain of Anion- and Cation-Conducting Cys-Loop Receptors.

Authors:  Nelli Mnatsakanyan; Sita Nirupama Nishtala; Akash Pandhare; Mariana C Fiori; Raman Goyal; Jonathan E Pauwels; Andrew F Navetta; Afzal Ahrorov; Michaela Jansen
Journal:  Biochemistry       Date:  2015-04-17       Impact factor: 3.162

6.  The activity of GAT107, an allosteric activator and positive modulator of α7 nicotinic acetylcholine receptors (nAChR), is regulated by aromatic amino acids that span the subunit interface.

Authors:  Roger L Papke; Nicole A Horenstein; Abhijit R Kulkarni; Clare Stokes; Lu W Corrie; Cheol-Young Maeng; Ganesh A Thakur
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

7.  The unique α4+/-α4 agonist binding site in (α4)3(β2)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology versus the (α4)2(β2)3 subtype.

Authors:  J Brek Eaton; Linda M Lucero; Harrison Stratton; Yongchang Chang; John F Cooper; Jon M Lindstrom; Ronald J Lukas; Paul Whiteaker
Journal:  J Pharmacol Exp Ther       Date:  2013-11-04       Impact factor: 4.030

8.  Atomic interactions of neonicotinoid agonists with AChBP: molecular recognition of the distinctive electronegative pharmacophore.

Authors:  Todd T Talley; Michal Harel; Ryan E Hibbs; Zoran Radic; Motohiro Tomizawa; John E Casida; Palmer Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-13       Impact factor: 11.205

9.  In silico models for the human alpha4beta2 nicotinic acetylcholine receptor.

Authors:  Esmael J Haddadian; Mary Hongying Cheng; Rob D Coalson; Yan Xu; Pei Tang
Journal:  J Phys Chem B       Date:  2008-10-11       Impact factor: 2.991

Review 10.  Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.

Authors:  Ana Sofía Vallés; María Virginia Borroni; Francisco J Barrantes
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.